Mortality rate of high cardiovascular risk patients with mild cognitive impairment

Teodora Yaneva-Sirakova1,3* & Latchezar Traykov2

People with mild cognitive impairment (MCI) may be at higher risk of death than normal aging ones. On the other hand, patients with cardiovascular risk factors are also with higher risk of death. It may be logical to question then if the combination of MCI and cardiovascular risk factors (in most cases arterial hypertension) can lead to higher mortality rate than expected both for high cardiovascular risk patients and for the general population. This hypothesis is important in the light of effective early screening and prophylaxis. The general death rate of patients with very high cardiovascular-risk was compared in the subgroups of normal cognition and MCI. We used MMSE and MoCA (reassessment 6 months apart), Geriatric Depression scale and 4-point version of the scale for evaluating the performance in instrumental activities of daily living (4-IADL) in 249 patients. The patients also had laboratory testing, ambulatory blood pressure monitoring, ECG and echocardiography. The general mortality rate of this very high cardiovascular-risk group was assessed 8–10 years afterwards and also compared to the general national death rate published for the corresponding period from the National Social Security Institute of Bulgaria. We registered significantly higher general death rate in patients with MCI and very high cardiovascular risk as compared to the group without MCI. The logistic regression analysis attributed approximately 14.6% of the mortality rate in this high-risk group to MCI. The major cardiovascular risk factor was arterial hypertension—with 63.85% of the patients with home blood pressure values not in the target range at the initial cognitive screening. During the neuropsychological reevaluation 56.43% were with poor control despite the multidrug antihypertensive regimen. It is known that MCI is correlated with cardiovascular risk factors with the leading role of arterial hypertension. We found that the combination of MCI and arterial hypertension can lead to higher mortality rate than in the general aging population. This has important clinical implications for the everyday practice.

More than 55 million people worldwide are diagnosed currently with dementia, with annual diagnosis rate of 10 million1. That makes dementia the seventh cause of death, with very high and ever rising rate of years of life lost, lost to disability and disability-adjusted life years2. For Bulgaria—around 100,000 people (out of 5 millions) are currently diagnosed with dementia, with possibly very high covered morbidity3. Dementia is correlated with elevated risk of death4. Mild cognitive impairment is a bridging state between normal aging and dementia, and is characterised with cognitive impairment with minimal impairment of instrumental activities of daily living as a main difference from dementia, and very high age adjusted prevalence rate (6.7% for ages 60–64, 8.4% for ages 65–69, 10.1% for 70–74, 14.8% for 75–79, and 25.2% for 80–84 years), cumulative dementia incidence 14.9% and no proven pharmacological treatment5. There are some studies in the general population of advance-aged people, that show higher mortality in people with cognitive impairment without manifest dementia6. Population-based studies suggest high impact of education, exercise and heart disease on death rate in advance-aged people (70–89) with mild cognitive impairment (MCI)7. A Norwegian register showed a significant loss in life expectancy for patients with MCI and all dementia subtypes (diagnosis made with neuropsychological testing)8. Patients with cardiovascular risk factors (diabetes, obesity, smoking, arterial hypertension, dyslipidemia, male sex, age) are also with elevated risk of death9. This high cardiovascular-risk group is also at an elevated risk for transition from MCI to dementia10. The leading risk factor is arterial hypertension. According to NCD Risk Factor Collaboration (NCD-RisC)11 hypertension morbidity doubled in the last 20 years and despite the universal measures...
control rates remained insufficient in the developed countries (around 50%) and poor in the developing countries (around 25%). Hypertension is the leading cause of more than 8.5 million deaths from stroke, ischemic coronary artery disease, renal disease. Hypertension is associated with higher risk of dementia and MCI in young adults and optimal blood pressure control before age of 70 was important for the reduction of cognitive impairment and mortality, but not in the very elderly group. Cardio-vascular risk factors, with the leading significance of arterial hypertension, modify the risk of death from dementia or MCI. Daen et al. found an U-shaped age-dependent association between mortality rate form dementia and systolic blood pressure. The conclusion for the diastolic blood pressure was the same, but less distinct. Based on the current knowledge, cardio-vascular risk factors, and especially arterial hypertension, in midlife lead to morphological and functional changes in the brain associated with cognitive decline later in life. The major mechanisms involved may be: lacunar infarcts, strategic strokes, small vessel disease, impaired blood–brain barrier and neuro-vascular unit functioning, reduced beta-amyloid clearance. A study form Mayo Clinic found that mortality in MCI patients varied with sex, education, history of heart disease, and physical activity. However, studies which make triple correlation between MCI, cardio-vascular risk factors and death rate are scarce.

**Hypothesis**

The combination of MCI and hypertension (and other cardio-vascular risk factors as well) may lead to even higher mortality rate than the current baseline.

This finding would be important in the light of effective early screening and prophylaxis, for real patients in the every day practice, who are not with a single isolated disease or risk factor. Crude death rate of Bulgaria for 2013 year for example was 14.4 per 1000 and it was much higher than the specific for EU 13 and WHO European region. Similarly, the mortality profile for Bulgaria is with very high percent for leading major cause of death per 100,000 population for diseases of the circulatory system (198.6/100,000 for men and 69.7/100,000 for women aged below 64 years—above that age, the mortality rate is even higher). This cardio-vascular death rate is between 1.6 (for males) and 1.8 (for females) times higher than the average rate in the Eastern European Region.

**Goal**

We aimed at analyzing if there was any difference in the mortality rate between the groups of high-cardio-vascular risk patients with and without MCI.

**Materials and methods**

For the given period from 2009 to 2012 year 269 patients with arterial hypertension underwent screening for MCI and reevaluated minimum 6 months after the initial evaluation. For 249 of them we found mortality data from the national registries and only these were included in the current analysis after 8–10 years of follow-up. All of them were with arterial hypertension and the majority of them—with additional cardiovascular risk factors (high and very high 10 year mortality risk defined by SCORE). The group was studied twice during the initial screening period. The second evaluation was at least 6 months after the inclusion (initial) assessment. That was the first phase of the study. During that phase we studied the cognitive performance of patients with arterial hypertension and various other cardio-vascular risk factors by performing a clinical screening with neuropsychological tests. After the second reevaluation the mortality rate of the patients was followed for 8–10 years. The first and the second evaluation included full medical history, physical examination, laboratory testing, ECG, echocardiography, ambulatory blood pressure monitoring, neuropsychological testing. The survey was conducted by two professionals: a cardiologist and a neurologist–neuropsychologist. The mortality rate was assessed via the national data base (National Social Security Institute of Bulgaria) and was done in mid 2019 year, before the beginning of the SARS Cov19 pandemic.

All the patients signed a written informed consent for participation in a scientific study mentored by Medical University Sofia, Bulgaria (Contract number 9D/26D/2011 from Medical University Sofia). The follow-up and mortality check were conducted in accordance with the Helsinki declaration for human research, GDPR recommendations and the local Ethical committee of Medical University Sofia, Bulgaria.

**Inclusion criteria.** Arterial hypertension with history of at least 1 year; left ventricular ejection fraction above 35%; antihypertensive treatment; regular self-measurement of brachial blood pressure.

**Exclusion criteria.** Acute coronary syndrome with or without ST elevation and indications for urgent coronary intervention; acute stroke; acute or chronic heart failure with ejection fraction less than 35%; acute kidney dysfunction or end stage chronic kidney disease and chronic dialysis; coma, sopor or somnolence; taking anti-depressants during the last 2 weeks; with impaired speech, vision, hearing; heavy head trauma; epilepsy; anemic syndrome; atrial fibrillation with suboptimal anticoagulation, verified with INR testing on enrolment; poorly controlled diabetes mellitus; hyperglycemic coma; astenoaodynamic syndrome; alcoholism; diagnosed psychiatric disease, diagnosed Alzheimer or other type of dementia.

Anamnesis and a comprehensive hypertensive history were gathered for every patient from the doctor in charge of the study. The responsible cardiologist took the physical examination. Basic laboratory testing was done as per protocol at hospitalization and included biochemistry, full blood count, liver enzymes, cardiac enzymes, lipid profile, TSH. Neuropsychological tests were conducted in private, by the certified doctor in charge of the study.
Methods for BP measurement. **Home-measured blood pressure (HMBP).** We taught the patients how to properly measure their blood pressure and to keep a diary for 3–7 days\(^2^3\). The target values were in compliance with current scientific recommendations\(^2^3\).

24-h ambulatory blood pressure monitoring (ABPM). Conducted with oscillometric sphygmanometer TM2430 (Boso), validated to the requirements of the European Society of Hypertension and the British Hypertension Society. The protocol was accepted as suitable for interpretation and diagnosis if it consisted of at least 70% valid measurements, distributed proportionally during the day and night. The patients were encouraged to behave without limitation in their daily activities and to keep the regular medication regimen. Mean test duration of the recording—24 h. The cuff was put on the non-dominant hand, with measurement intervals at 15 min during the day and at 30 min during the night, with passive day and night period registration (7.00 a.m.–10.00 p.m.). Dipping index and blood pressure variability were automatically acquired.

Neuropsychological tests used. They were conducted after full explanation of the purpose, in private, at least 1 h apart.

**Mini mental state examination (MMSE)**\(^2^4\). The “Gold Standard” in dementia clinical screening, however, quite insensitive to the earliest phases. The cognitive domains, tested in MMSE are: orientation, registration, attention and calculation (serial 7-s or spelling backwards), recall, language and praxis (naming, repetition, 3-stage command, reading, writing, coping). We used a threshold for cognitive impairment 24 points from total of 30. The time given for completion of the test was 5–10 min.

**Montreal cognitive assessment (MoCA)**\(^2^5\). More sensitive and specific for the clinical diagnosis of the earliest stages of cognitive impairment. It is a 10-min compilation of neuropsychological tests aimed at evaluating frontal executive functioning and attention. We used the generally accepted threshold of 26 (out of maximal 30 points). Cognitive domains tested via MoCA were: attention, concentration, executive functioning, language, memory, visual-constructional, abstraction, delayed recall, orientation.

**Geriatric Depression Scale (GDS)**\(^2^6\). The coexistence of depression and dementia and the unclear association of depression with MCI led us to include this test in the initial evaluation. The test was used to study dementia patients and to explain whether it was correlated with earlier stages of cognitive impairment.

**4-point version of the scale for evaluating the performance in instrumental activities of daily living (4-IADL)**\(^2^7\). Impaired daily functioning is art of dementia diagnosis. The test was used to better define patients with advanced cognitive impairment.

Statistical methods. SPSS 19 was used for the statistical analysis. Descriptive analysis, \(t\) test, correlation analysis is used depending on the particular question. A possible association between neuropsychological tests’ results and mortality in high risk patients was assessed with logistic regression analysis. The statistic was done by a certified statistician from the National Statistical Institute of Bulgaria. The precise method, which was used depended on the means were compared, or we studied the correlation. The standard for the medical statistics 95% confidence interval was used.

Statement of ethics. Written informed consent was obtain from all participants in the study. The study was mentored by Medical University Sofia, Bulgaria—under Contract number 9D/26D/2011 from Medical University Sofia. The study and the follow-up were conducted in accordance with the Helsinki declaration for human research and with the local Ethical committee of Medical University Sofia, Bulgaria. For the mortality rate check—ethical approval was not required as the data were fully anonymised.

Study approval and consent to participate statements. Not applicable as this was a retrospective analysis—ethical approval was not required as the data were fully anonymized. The initial phase of neuropsychological testing and reevaluation of cardio-vascular patients was done under Contract number 9D/26D/2011 from Medical University Sofia. All initial physical examination and neuropsychological tests we done after signing informed consent.

Results

Here we describe the follow-up results for the difference of all-cause mortality of the initially studied population. Results from the first phase have already been published\(^2^8–3^0\).

**Characteristics of the studied population.** 249 patients were included in this analysis of the mortality rate (for whom we had complete medical and passport data). During the follow-up 64 patients (25.7%) died, out of whom with MCI (MoCA < 26) were 53 (82.81%). The sex distribution was: 174 (69.9%) females and 75 (30.1%) males. The mean age was 67.83 ± 8.93 years.

All the patients had arterial hypertension (100%). The majority also had a variety of other cardio-vascular risk factors. The valid percent for high and very high cardio-vascular risk as assessed with SCORE was 19.7% (49 patients) for the high-risk group and 48.2% (120 patients) for the very high-risk group. Twenty-four—24
All-cause mortality rate analysis. Every patient had 2 neuropsychological tests taken at least 6 months apart. They were designated as MMSE initial and reevaluation, respectively MoCA initial and reevaluation. We assessed mortality rate 8–10 years after the second test. Sixty-four (25.7%) of the patients died for this period.

The yearly all-cause mortality rate for the last few years before the SARS Cov19 pandemic for Bulgaria was about 4.1–15.4/1000. The relative all-cause mortality rate of this studied population was about 25.7/1000 patient on yearly basis—1.67 times higher.

The percent of dead patient rates with low MoCA results (≤25 points) was 21.28% in comparison with only 4.42% dead in those with MoCA > 25. The distribution of the percent of the dead for MMSE is 6.83% in the group of MMSE ≤ 24 and 18.87% in those with MMSE > 24.

We used logistic regression model to analyze to what extend MMSE reevaluation and MoCA reevaluation influenced death rate in this group of patients with arteria hypertension and primarily high or very high cardio-vascular risk. The Omnibus Tests of model coefficients showed ϕ = 0.0001, i.e. the model had some explanatory capacity. However, the Negelkerke R square was 0.146 and thus only 14.6% of the death rate could be explained by the values of the given neuropsychological test. The regression coefficient only for MoCA reevaluation was significant (p = 0.023; Exp(B) 0.864). Thus, for every point elevation of the MoCA reevaluation result, the odds that the patient was dead was elevated with 0.864, that means that it was actually lowered with 13.6%. For MMSE reevaluation the odds the patient was dead was lowered with 8.9% for every point elevation of the value of the test. We could not comment on the MMSE mortality rate as there was no significant difference if the P-value is 0.324 (Exp(B) 0.911). Much larger group should be analyzed to properly define if there was significance.

For further analysis we controlled for confounders such as: age, blood pressure variables, smoking, diabetes, peripheral artery disease, stroke, myocardial infarction, atrial fibrillation, chronic kidney disease, creatinine values, obesity, IADL, dyslipidemia, neuropsychological tests' results. The explained variation in the dependent variable (death rate) based on our model was 35.5% (Nagelkerke R²). We used Forward LR binary logistic regression with dependent variable mortality for the selected time period. The CI for exp(B) was 95%, probability for stepwise entry was 0.05 and for removal—0.10. The percentage accuracy in classification was 79.7%. The variables, that remained in the equation at step 6 were MoCA reevaluation p = 0.002, B = −0.184, Exp(B) 0.832, CI 0.741–0.934 (higher MoCA points had a protective effect); MMSE initial p = 0.049, B = −0.201, Exp(B) 0.818, CI 0.670–0.999 (higher MMSE points had a protective effect); atrial fibrillation frequency p = 0.032, B = 1.123, Exp(B) 3.073, CI 1.104–8.553 (risk factor); diastolic blood pressure p = 0.048, B = −0.032, Exp(B) 0.969, CI 0.939–1.000 (higher values had mild protective effect in this age group).

Discussion
The results support the thesis, that lower results from neuropsychological tests (the more sensitive one—MoCA) and MCI in patients with arterial hypertension and high/very high cardiovascular risk lead to an elevated death rate. The mean all-cause mortality (25.7/1000) in the group as a whole is higher than the mean for Bulgaria (1.67 times higher), for the region and for Europe (10.8/1000). An important result is that 82% of the deceased in our studied group were with MCI. The regression analysis showed that 14.6% of the death rate can be explained by MCI (assessed with MoCA), that leads us to the conclusion that the cumulative negative effect of MCI and arterial hypertension may be very high with respect to mortality rate. A study of Contador et al.,34 found that dementia mortality, but not cardio-vascular mortality, increased in patients for a period of 5 years follow-up. It was difficult to compare our results to this, as we do not have clear mortality rate by subtypes. So we lack the distinction between the reasons for mortality in our MCI patients. Another study of 2619 patients with cardiovascular risk factors35 found that MCI was associated with significant comorbidity, which impairs patients' compliance and adherence to treatment, and thus the quality of cardiovascular treatment, which may be correlated with elevated death rate. A study of people above age of 60 from the National Health and Nutrition Examination Survey36 found that cognitive impairment with concomitant systemic vascular disease increased the risk of all-cause and cardio-vascular mortality. We found two studies to back the hypothesis for the cumulative effect of arterial...
| Dead 1/alive 0 | N  | Mean ± SD | p (CI)        |
|---------------|----|-----------|---------------|
| Age at inclusion (years) |    |           |               |
| 1             | 64 | 71.33     | 8.57          |
| 0             | 185| 66.62     | 8.75          |
| MoCA initial (points) |    |           |               |
| 1             | 64 | 22.70     | 3.79          |
| 0             | 185| 24.61     | 3.17          |
| MMSE initial (points) |    |           |               |
| 1             | 64 | 26.63     | 2.80          |
| 0             | 185| 27.99     | 1.79          |
| MoCA reevaluation (p) |    |           |               |
| 1             | 64 | 21.52     | 4.16          |
| 0             | 185| 24.23     | 3.49          |
| MMSE reevaluation (p) |    |           |               |
| 1             | 64 | 25.77     | 3.02          |
| 0             | 182| 27.47     | 2.16          |
| Day SBP initial (mmHg) |    |           |               |
| 1             | 29 | 142.78    | 21.31         |
| 0             | 97 | 136.15    | 18.80         |
| DaySBP reev. (mmHg) |    |           |               |
| 1             | 42 | 138.76    | 21.54         |
| 0             | 134| 136.24    | 17.39         |
| Day DBP initial (mmHg) |    |           |               |
| 1             | 29 | 78.30     | 9.57          |
| 0             | 98 | 77.48     | 10.07         |
| Day DBP reev. (mmHg) |    |           |               |
| 1             | 42 | 77.96     | 9.03          |
| 0             | 135| 78.56     | 9.17          |
| DayPP initial (mmHg) |    |           |               |
| 1             | 29 | 64.45     | 13.56         |
| 0             | 96 | 58.54     | 12.34         |
| DayPP reev. (mmHg) |    |           |               |
| 1             | 42 | 60.80     | 15.90         |
| 0             | 134| 57.45     | 11.31         |
| NightSBP initial (mmHg) |    |           |               |
| 1             | 29 | 134.57    | 22.13         |
| 0             | 98 | 124.75    | 20.43         |
| NightSBP reev. (mmHg) |    |           |               |
| 1             | 42 | 129.85    | 25.04         |
| 0             | 135| 135.36    | 46.86         |
| NightDBP initial (mmHg) |    |           |               |
| 1             | 29 | 70.56     | 7.82          |
| 0             | 98 | 69.48     | 9.86          |
| NightDBP reev. (mmHg) |    |           |               |
| 1             | 42 | 70.70     | 10.74         |
| 0             | 135| 70.16     | 12.72         |
| NightPP initial (mmHg) |    |           |               |
| 1             | 29 | 64.08     | 15.63         |
| 0             | 96 | 55.34     | 13.99         |
| NightPP reev. (mmHg) |    |           |               |
| 1             | 42 | 59.16     | 17.18         |
| 0             | 134| 54.72     | 13.67         |
| Home SBP initial (mmHg) |    |           |               |
| 1             | 64 | 142.47    | 19.98         |
| 0             | 185| 141.14    | 18.03         |
| Home DBP initial (mmHg) |    |           |               |
| 1             | 64 | 82.89     | 10.94         |

Continued
hypertension and MCI (triple correlation)—the Kangwha Cohort Study\(^{34}\) and Gerontological Regional Database cohort study\(^ {35}\). The second one, also with the finding that low SBP in elderly above 85 years was associated with increased mortality risk, with the possible explanation—hypoperfusion.

Several possible explanations can be given for the observed association between MCI and high cardiovascular risk profile and hypertension. Reduced compliance to treatment, accelerated vascular impairment and impairment of the central autoregulatory mechanisms of cerebral perfusion, blood pressure, neurohormonal and vascular tone maintenance. All these mechanisms have been proven in models of hypertension and of dementia. However, their simultaneous action has been understudied in pathophysiological models. If they were proven both preclinically, clinically and on population level, that can lead to better surveillance of patients with MCI and hypertension—a screening for hypertension in MCI patients and vice-versa for timely prophylaxis.

### Table 1. Descriptive statistic of the followed population and comparison between the mean values for deceased and for the alive.

|                     | Dead 1/alive 0 | N   | Mean ± SD | p (CI) |
|---------------------|----------------|-----|-----------|--------|
| **Home PP initial (mmHg)** |                |     |           |        |
| 0                   | 185            | 83.70 | 10.46     | NS     |
| 1                   | 64             | 59.27 | 14.37     |        |
| 0                   | 185            | 57.30 | 12.39     | NS     |
| **Home SBP reev. (mmHg)** |                |     |           |        |
| 1                   | 52             | 137.40 | 21.36    |        |
| 0                   | 150            | 135.55 | 15.50    | NS     |
| **Home DBP reev. (mmHg)** |                |     |           |        |
| 1                   | 52             | 80.10  | 11.44     |        |
| 0                   | 150            | 80.48  | 9.92      | NS     |
| **Home PP reev. (mmHg)** |                |     |           |        |
| 1                   | 52             | 57.88  | 13.76     |        |
| 0                   | 150            | 55.34  | 11.01     | NS     |
| **HT history (years)** |                |     |           |        |
| 1                   | 64             | 15.80  | 10.64     |        |
| 0                   | 185            | 12.13  | 9.58      | 0.011 (0.85 to 6.48) |
| **Creatinine (mkmol/l)** |                |     |           |        |
| 1                   | 62             | 119.00 | 9.25     |        |
| 0                   | 184            | 97.22  | 25.02     | 0.001 (8.78 to 34.78) |
| **Office SBP (mmHg)** |                |     |           |        |
| 1                   | 63             | 143.57 | 27.92    |        |
| 0                   | 183            | 144.33 | 21.77    | NS     |
| **Office DBP (mmHg)** |                |     |           |        |
| 1                   | 63             | 84.37  | 12.59     |        |
| 0                   | 183            | 86.02  | 11.37     | NS     |
| **Office PP (mmHg)** |                |     |           |        |
| 1                   | 63             | 59.21  | 19.08     |        |
| 0                   | 183            | 58.31  | 14.80     | NS     |

**Figure 1.** Valid percent of the risk factors in the group of patients.
There was not any statistically significant difference between the mean blood pressure values, cardio-vascular risk factors and diseases between the deceased and the alive patients, except for hypertension history (higher in the dead), serum creatinine (higher for the dead), pulse pressure (higher in the dead), age and neuropsychological tests’ results. The results from MoCA and MMSE were lower in the patients who were registered dead in the following years. The logistic regression analysis showed that every single point elevation in MoCA leads to 13.6% lower death rate. Such results are being reported for the first time for an Eastern European population with high cardio-vascular risk.

It should be noted that women were more than men in the group. There were several reasons for this. Women were relatively more willing to participate in such studies. Also, the relative percent females above age 65 years was relatively higher than males. There was not any significant difference between the two sexes in terms of cardio-vascular disease or MCI.

These results show that 14.6% of the death rate can be explained by the results from the neuropsychological test (MoCA). This percent, however low in general, is relatively high if we consider that the group consists of patients with primarily high and very high cardio-vascular risk. In a study of Stewart et al. found that in patients with stable coronary heart disease, cognitive performance was associated with modifiable risk factors, educational status and ethnic region.

Discussing the relative percent dead in those with MCI we should bear in mind the following commentaries: The correlation between MMSE and MoCA is very high positive (Pearson r > 0.8, p < 0.001). Thus this discrepancy can be attributed to the very high MMSE threshold used (24), and to the low sensitivity of the test. With lower threshold of MMSE, the death rate distribution is in accord with the general tendency, registered with MoCA. However, our aim was to show the real-world results, strengths and disadvantages of the neuropsychological tests in high-risk cardio-vascular patients, the way we see them in the everyday practice. Recently there have been papers, that review the diagnostic thresholds of MMSE and MoCA. This can lead to significant change and clarification of the general mortality rate. However, we stuck to the initial official recommendations, as these new and different thresholds are only in isolated studies.

Conclusion
It is known that MCI is correlated with cardiovascular risk factors and primarily arterial hypertension. We found that the combination of MCI and AH can lead to higher mortality rate. This has important clinical implications for primary prophylaxis of cognitive decline and primary secondary prophylaxis in high risk patients. We will study further this issue to define in detail the factors responsible for the higher death rate in this group.

Limitations
It could have been interesting to find the rate of progression for the given time of 8–10 years of patients with MCI at the first two neuropsychological assessment events. We plan to conduct a second reevaluation with neuropsychological testing and ambulatory blood pressure monitoring in the upcoming months.

Data availability
The datasets generated during and analyzed during the current study are not publicly available due to initial authors’ decision, but are available from the corresponding author on reasonable request in anonymised version and after discussion with all the authors.

Received: 15 January 2022; Accepted: 4 May 2022
Published online: 13 July 2022

References
1. https://www.who.int/news-room/fact-sheets/detail/dementia (access on 02.03.2022).
2. https://www.dementiastatistics.org/statistics/disability-and-life-lost/ (access on 02.03.2022).
3. https://alzheimers-bg.org/ (access on 02.03.2022).
4. Hatcher, S. Dementia in advanced age led to higher mortality rates and shortened life. Evid. Based Mental Health 3, 57. https://doi.org/10.1136/ebmh.3.2.57 (2000).
5. Petersen, R. et al. Practice guideline update summary: Mild cognitive impairment. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 90(3), 126–135 (2018).
6. Perna, L. et al. Cognitive impairment, all-cause and cause-specific mortality among non-demented older adults. Age Aging 44(3), 445–451 (2015).
7. Vassilaki, M. et al. Mortality in mild cognitive impairment varies by subtype, sex and lifestyle factors. The Mayo Clinic Study of Aging. J. Alzheimers Dis. 45(4), 1237–1245 (2015).
8. Strand, B. et al. Survival and years of life lost in various aetiologies of dementia, mild cognitive impairment (MCI) and subjective cognitive decline (SCD) in Norway. PLoS One. https://doi.org/10.1371/journal.pone.0204436 (2018).
9. Visseren, F. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur. Heart J. 42(34), 3227–3337 (2021).
10. Kryscio, R. et al. Adjusting for mortality when identifying risk factors for transition to MCI and dementia. J. Alzheimers Dis. 35(4), 823–832 (2013).
11. Zhou, B. et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 398, P957–P980 (2021).
12. Olsen, M., Angell, S. & Asma, S. A call to action and lifestyle strategy to address the global burden of raised blood pressure on current and future generations: The Lancet Commission on hypertension. Lancet 388, 2665–2712 (2016).
13. Walker, K. et al. Association of midlife to late-life blood pressure patterns incident dementia. JAMA 322(6), 535–545 (2019).
14. Jung, H. et al. Associations of hypertension burden on subsequent dementia: Population-based cohort study. Sci. Rep. 11, 12291 (2021).
15. Hestad, K., Engedal, K., Selbekk, G. & Strand, B. Blood pressure in dementia, mild cognitive impairment, and subjective cognitive decline related to time of death. *Brain Behav. Aging* **11**(7), e02166 (2021).
16. Lee, C. H. et al. Blood pressure levels and risk of dementia: A nationwide study of 4.5 million people. *Hypertension* **79**, 218–229 (2021).
17. Meguro, K. et al. Prognosis of vascular mild cognitive impairment includes vascular dementia onset and death by cardiovascular disease: Reanalysis from the Osaki-Tajiri project. *J. Stroke Cerebrovasc. Dis.* **21**(7), 607–611 (2012).
18. Dalen, J. et al. Association of systolic blood pressure with dementia risk and the role of age, U-shaped associations, and mortality. *JAMA Intern. Med.* **182**(2), 142–152 (2022).
19. You, D., Swaefager, W. & Black, S. *Pathophysiology of Vascular Cognitive Impairment (I): Theoretical Background*. Stroke Revisited (Springer, 2020). doi:https://10.1007/978-981-10-1433-8_7
20. Vassilaki, M. et al. Mortality in mild cognitive impairment varies by subtype, sex and lifestyle factors: The Mayo Clinic Study of Aging. *J. Alzheimers Dis.* **45**(4), 1237–1245 (2015).
21. http://www.euro.who.int/__data/assets/pdf_file/0003/354036/214827_WHO_BULGARIA_PROFILE_EN.pdf?ua=1 (access on 05.07.2020).
22. O’Brien, E. et al. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. *J. Hypertens.* **23**, 697–701 (2005).
23. Kjeldsen, S., Narkiewicz, K., Burnier, M. & Oparil, S. 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension. *Blood Press.* **27**(6), 313. https://10.1080/08037051.2018.1530564 (2018).
24. http://www.heartinstitutehd.com/Misc/Forms/MMSE.1276128605.pdf (access on 12.04.2009).
25. www.mocastest.org/default.asp (access on 12.05.2009).
26. Burke, W., Houston, M., Boast, S. & Roccaforte, W. Use of the Geriatric Depression Scale in dementia of the Alzheimer type. *J. Am. Geriatr. Soc.* **37**(9), 856–860 (1989).
27. Barber-Georgeau, P., Dartigues, J. & Lerenneur, L. Four Instrumental Activities of Daily Living Score as a predictor of one-year incident dementia. *Age Aging* **22**(6), 457–463 (1993).
28. Yaneva-Sirakova, T., Tarnovska-Kadreva, R. & Traykov, L. Pulse pressure and mild cognitive impairment. *J. Cardiovasc. Med.* **13**(11), 735–740 (2012).
29. Yaneva-Sirakova, T., Tarnovska-Kadreva, R. & Traykov, L. The role of suboptimal home-measured blood pressure control for cognitive decline. *Dement. Geriatric Cogn. Disord. Extra* **2**(1), 112–119 (2012).
30. Yaneva-Sirakova, T., Traykov, L., Petrova, J., Gruev, I. & Vassilev, D. Screening for mild cognitive impairment in patients with cardio-vascular risk factors. *Neuropsychol. Dis. Treat.* **13**, 2925 (2017).
31. Contador, I. et al. Cause of death in mild cognitive impairment: A prospective study (NEDICES). *Eur. J. Neurol.* **21**(2), 253–269 (2014).
32. Ball, J., Carrington, M., Chan, Y. & Stewart, S. Mild cognitive impairment across the spectrum of cardiovascular disease. *Circulation* **136**, A16240 (2017).
33. Zhu, Z. H. & Liao, H. Impact of cognitive impairment and systemic vascular comorbidities on risk of all-cause and cardiovascular mortality: National Health and Nutrition Examination Survey 1999 to 2002. *Int. J. Cardiol.* https://10.1016/j.ijcard.2019.11.131 (2019).
34. Gombojav, B., Yi, S., Sull, J., Nam, C. & Ohrr, H. Combined effects of cognitive impairment and hypertension on total mortality in elderly people: The Kangwha Cohort Study. *Gerontology* **57**, 490–496 (2011).
35. Weidung, B., Littbrand, H., Nordstrom, P., Carlberg, B. & Gustafson, Y. The association between SBP and mortality risk differs with level of cognitive function in very old individuals. *J. Hypertens.* **34**(4), 745–752 (2016).
36. http://www.nsi.bg/bg/content/767/%D0%B4%D0%B5%D0%BC%D0%BE%D0%B3%D1%80%D0%BA%D0%B0-%D0%B8-%D1%81%D0%BA%D0%B0-%D1%82%D0%B8%D1%86%D0%B8%D0%B0-%D1%88%D0%BA%D0%B0 (access on 05.07.2020).
37. Stewart, R., Held, C., Krug-Gourley, S., Waterworth, D., Stebbins, A., Chiswell, K. et al. Cardiovascular and lifestyle risk factors and cognitive function in patients with stable coronary heart disease. *JAMA*. https://10.1161/JAMA.118.010841 (access on 05.07.2020).
38. Barkis, M. & Sorrentino, M. *Hypertension: A Companion to Bowerson’s Heart Disease E-Book* 3rd edn. (Elsevier, 2018).
39. Milani, S., Marsisike, M., Cottler, L., Chen, X. & Xtrillie, C. Optimal cutoffs for the Montreal Cognitive Assessment vary by race and ethnicity. *Alzheimers Dement. (Amst)* **10**, 773–781 (2018).
40. US Preventive Services Task Force. Screening for Cognitive Impairment in Older Adults: Recommendaion Statement. *Am. Fam. Physician* **91**(6) (2015). http://www.aafp.org/afp/2015/0315/od2.html (access on 05.07.2020). http://www.mocastest.org/ according to which the two previous neuropsychological evaluations in our study were done.

Author contributions
Both authors have equally contributed to data collecting, management, research, idea, analysis, statistics, manuscript writing. Acad. Prof. Dr. L.T., MD, PhD, DSc is the Head of the research team.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to T.Y.-S.

Reprints and permissions information
is available at [www.nature.com/reprints](http://www.nature.com/reprints).

Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
